Purpuric drug eruption with leukocytoclastic vasculitis due to gefitinib

Journal of Dermatology

Volumn 37, Issue 6, 2010, Pages 562-564

  Uchimiya, Hiroshi ^a   Higashi, Yuko ^a   Kawai, Kazuhiro ^a   Kanekura, Takuro ^a  

^a KAGOSHIMA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

GEFITINIB; IMMUNOGLOBULIN A; ANTINEOPLASTIC AGENT; QUINAZOLINE DERIVATIVE;

AGED; CASE REPORT; DRUG ERUPTION; DRUG INTERMITTENT THERAPY; DRUG WITHDRAWAL; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOFLUORESCENCE TEST; LEG PAIN; LETTER; LEUKOCYTOCLASTIC VASCULITIS; LUNG CANCER; PAPULE; PURPURIC RASH; RETREATMENT; SKIN BIOPSY; TREATMENT DURATION; CHEMICALLY INDUCED; COMPLICATION; PURPURA;

AGED; ANTINEOPLASTIC AGENTS; FEMALE; HUMANS; PURPURA; QUINAZOLINES; VASCULITIS, LEUKOCYTOCLASTIC, CUTANEOUS;

EID: 77952772832     PISSN: 03852407     EISSN: 13468138     Source Type: Journal    
DOI: 10.1111/j.1346-8138.2010.00896.x     Document Type: Letter

References (7)

1. Baselga J. New therapeutic agents targeting the epidermal growth factor receptor. J Clin Oncol 2000 18 : 54 59.
2. Nanney LB, Magrid M, Stoscheck CM, Carpenter G, King LE. Comparison of epidermal growth factor binding and receptor distribution in normal human epidermis and epidermal appendages. J Invest Dermatol 1984 83 : 385 393.
3. Kurokawa I, Endo K, Hirabayashi M. Purpuric drug eruption possibly due to gefitinib (Iressa®). Int J Dermatol 2005 44 : 167 168.
4. Fernández-Guarino M, Marquet Ryan A, Pérez-García B, Gónzalez-López C, Jaén Olasolo P. Necrotizing vasculitis due to gefitinib (Iressa®). Int J Dermatol 2007 46 : 890 891.
5. Sheen YS, Hsiao CH, Chu CY. Severe purpuric xerotic dermatitis associated with gefitinib therapy. Arch Dermatol 2008 144 : 269 270.
6. Lee MW, Seo CW, Kim SW et al. Cutaneous side effects in non-small cell lung cancer patients treated with Iressa (ZD1839), an inhibitor of epidermal growth factor. Acta Derm Venereol 2004 84 : 23 26.
7. Uchihara M, Ejima T, Uchihira T, Araki J, Kamei T. Cutaneous side effects in 19 lung cancer patients treated with gefitinib. Nishi-Nihon Hihu 2004 66 : 602 607 (in Japanese).